Nanomaterials,
Journal Year:
2022,
Volume and Issue:
12(14), P. 2337 - 2337
Published: July 7, 2022
Neurodegenerative
disorders
(NDs)
affect
a
great
number
of
people
worldwide
and
also
have
significant
socio-economic
impact
on
the
aging
population.
In
this
context,
nanomedicine
applied
to
neurological
provides
several
biotechnological
strategies
nanoformulations
that
improve
life
expectancy
quality
patients
affected
by
brain
disorders.
However,
available
treatments
are
limited
presence
blood-brain
barrier
(BBB)
blood-cerebrospinal
fluid
(B-CSFB).
regard,
nanotechnological
approaches
could
overcome
these
obstacles
updating
various
aspects
(e.g.,
enhanced
drug-delivery
efficiency
bioavailability,
BBB
permeation
targeting
parenchyma,
minimizing
side
effects).
The
aim
review
is
carefully
explore
key
elements
different
summarize
nanomaterials
for
neurodegeneration
therapy
looking
at
types
nanocarriers.
Moreover,
nutraceutical-loaded
nanoparticles
(NPs)
synthesized
NPs
using
green
discussed
underling
need
adopt
eco-friendly
procedures
with
low
environmental
impact.
proven
antioxidant
properties
related
natural
products
provide
an
interesting
starting
point
developing
efficient
nanotools
useful
neuroprotection.
Molecular Psychiatry,
Journal Year:
2022,
Volume and Issue:
27(6), P. 2659 - 2673
Published: March 31, 2022
Abstract
The
blood-brain
barrier
(BBB)
is
vital
for
maintaining
brain
homeostasis
by
enabling
an
exquisite
control
of
exchange
compounds
between
the
blood
and
parenchyma.
Moreover,
BBB
prevents
unwanted
toxins
pathogens
from
entering
brain.
This
barrier,
however,
breaks
down
with
age
further
disruption
a
hallmark
many
age-related
disorders.
Several
drugs
have
been
explored,
thus
far,
to
protect
or
restore
function.
With
recent
connection
gut
microbiota,
microbial-derived
metabolites
explored
their
capabilities
physiology.
review,
will
focus
on
components
that
make
up
BBB,
dissect
levels
discuss
current
therapeutics
maintain
integrity
discoveries
effects
Colloids and Surfaces B Biointerfaces,
Journal Year:
2022,
Volume and Issue:
221, P. 112999 - 112999
Published: Nov. 2, 2022
The
blood-brain
barrier
(BBB)
restricts
the
access
of
therapeutic
agents
to
brain,
complicating
treatment
neurological
diseases,
such
as
Alzheimer's
disease
(AD),
Parkinson's
(PD),
multiple
sclerosis
(MS),
glioma,
etc.
To
overcome
this
limitation
and
improve
drug
delivery
central
nervous
system
(CNS),
potential
nanocarriers,
including
lipid-based
nanosystems,
has
been
explored.
Through
active
targeting,
surface
nanocarriers
can
be
modified
with
ligands
that
interact
BBB,
enhancing
their
uptake
penetration
across
brain
endothelium
by
different
physiological
mechanisms,
receptor-
or
transporter-mediated
transcytosis.
This
review
seeks
provide
an
overview
targeting
in
delivery,
while
highlighting
functionalized
lipid
treat
diseases.
Therefore,
first
sections,
we
discuss
importance
CNS
present
commonly
used
for
functionalization,
well
summarize
state
art
most
recent
relevant
studies
surface-modified
nanosystems
developed
disorders.
Lastly,
challenges
hindering
clinical
translation
are
discussed,
critical
insights
future
perspectives
outlined.
Although
some
limitations
have
identified,
it
is
expected
upcoming
years
these
will
established
approach.
Fluids and Barriers of the CNS,
Journal Year:
2024,
Volume and Issue:
21(1)
Published: July 19, 2024
Abstract
Background
Maintaining
the
structural
and
functional
integrity
of
blood–brain
barrier
(BBB)
is
vital
for
neuronal
equilibrium
optimal
brain
function.
Disruptions
to
BBB
performance
are
implicated
in
pathology
neurodegenerative
diseases.
Main
body
Early
indicators
multiple
disorders
humans
animal
models
include
impaired
stability,
regional
cerebral
blood
flow
shortfalls,
vascular
inflammation
associated
with
dysfunction.
Understanding
cellular
molecular
mechanisms
dysfunction
crucial
elucidating
sustenance
neural
computations
under
pathological
conditions
developing
treatments
these
This
paper
initially
explores
definition
BBB,
along
signaling
pathways
regulating
flow,
inflammation.
Subsequently,
we
review
current
insights
into
dynamics
Alzheimer’s
disease,
Parkinson's
amyotrophic
lateral
sclerosis,
sclerosis.
The
concludes
by
proposing
a
unified
mechanism
whereby
contributes
disorders,
highlights
potential
BBB-focused
therapeutic
strategies
targets,
outlines
lessons
learned
future
research
directions.
Conclusions
breakdown
significantly
impacts
development
progression
diseases,
unraveling
underlying
elucidate
how
sustained
devise
approaches.
Exploration,
Journal Year:
2021,
Volume and Issue:
1(3)
Published: Dec. 1, 2021
Abstract
Neurodegenerative
diseases
(NDs)
are
a
class
of
heterogeneous
that
includes
Alzheimer's
disease,
Parkinson's
Huntington's
and
amyotrophic
lateral
sclerosis.
Mitochondria
play
an
important
role
in
oxidative
balance
metabolic
activity
neurons;
therefore,
mitochondrial
dysfunction
is
associated
with
NDs
mitochondria
considered
potential
treatment
target
for
NDs.
Several
obstacles,
including
the
blood‐brain
barrier
(BBB)
cell/mitochondrial
membranes,
reduce
efficiency
drug
entry
into
lesions.
Therefore,
variety
neuron
targeting
strategies
has
been
developed.
Among
them,
nanotechnology‐based
treatments
show
especially
promising
results.
Owing
to
their
adjustable
size,
appropriate
charge,
lipophilic
surface,
nanoparticles
(NPs)
ideal
theranostic
system
crossing
BBB
neuronal
mitochondria.
In
this
review,
we
discussed
dysfunctional
ND
pathogenesis
as
well
physiological
barriers
various
strategies.
We
also
reviewed
use
advantages
NPs
(including
organic,
inorganic,
biological
membrane‐coated
NPs)
diagnosis
Finally,
summarized
evidence
possible
NP‐based
systems
dysfunction‐related
Pharmaceutics,
Journal Year:
2022,
Volume and Issue:
14(9), P. 1976 - 1976
Published: Sept. 19, 2022
Alzheimer's
disease
(AD)
is
a
neurodegenerative
disorder
characterized
by
cognitive
and
behavioral
impairment.
Curcumin-loaded
mesoporous
silica
nanoparticles
(MSN-CCM)
can
overcome
the
drawbacks
related
to
free
curcumin
(CCM)
clinical
application,
such
as
water
insolubility
low
bioavailability,
besides
acting
over
main
causes
associated
AD.
A
thermo-responsive
hydrogel
an
interesting
approach
for
facilitating
administration
of
nanosystem
via
nasal
route,
well
overcoming
mucociliary
clearance
mechanisms.
In
light
this,
MSN-CCM
were
dispersed
in
evaluated
through
vitro
vivo
assays.
The
MSNs
successfully
physicochemical
analysis
high
value
CCM
encapsulation
efficiency
(EE%,
87.70
±
0.05)
was
achieved.
designed
(HG)
rheology,
texture
profile
analysis,
ex
mucoadhesion,
showing
excellent
mechanical
mucoadhesive
properties.
Ex
permeation
studies
HG@MSN-CCM
showed
values
(12.46
1.08
28.40
1.88
μg
cm-2
CCM,
respectively)
porcine
mucosa.
performed
streptozotocin-induced
AD
model
confirmed
that
reverted
deficit
mice,
potential
formulation
treatment
Pharmaceutics,
Journal Year:
2022,
Volume and Issue:
14(1), P. 185 - 185
Published: Jan. 13, 2022
Amyotrophic
lateral
sclerosis
(ALS)
is
a
neurodegenerative
disease
with
very
poor
prognosis.
Its
treatment
hindered
by
lack
of
new
therapeutic
alternatives
and
the
existence
blood–brain
barrier
(BBB),
which
restricts
access
drugs
commonly
used
in
ALS,
such
as
riluzole,
to
brain.
To
overcome
these
limitations
increase
brain
targeting,
riluzole-loaded
nanostructured
lipid
carriers
(NLC)
were
prepared
functionalized
lactoferrin
(Lf),
facilitating
transport
across
BBB
interacting
Lf
receptors
expressed
endothelium.
NLC
characterized
respect
their
physicochemical
properties
(size,
zeta
potential,
polydispersity
index)
well
stability,
encapsulation
efficiency,
morphology,
vitro
release
profile,
biocompatibility.
Moreover,
crystallinity
melting
behavior
assessed
DSC
PXRD.
Nanoparticles
exhibited
initial
mean
diameters
between
180
220
nm
index
below
0.3,
indicating
narrow
size
distribution.
remained
stable
over
at
least
3
months.
Riluzole
efficiency
was
high,
around
94–98%.
FTIR
protein
quantification
studies
confirmed
conjugation
on
surface
nanocarriers,
TEM
images
showing
that
presented
smooth
uniform
spherical
shape.
An
MTT
assay
revealed
nanocarriers
developed
this
study
did
not
cause
substantial
reduction
viability
NSC-34
hCMEC/D3
cells
riluzole
concentration
up
10
μM,
being
therefore
biocompatible.
The
results
suggest
Lf-functionalized
are
suitable
promising
delivery
system
target
Pharmaceutics,
Journal Year:
2022,
Volume and Issue:
14(4), P. 836 - 836
Published: April 11, 2022
Neurodegenerative
disorders
including
Alzheimer’s,
Parkinson’s,
and
dementia
are
chronic
advanced
diseases
that
associated
with
loss
of
neurons
other
related
pathologies.
Furthermore,
these
involve
structural
functional
defections
the
blood-brain
barrier
(BBB).
Consequently,
advances
in
medicines
therapeutics
have
led
to
a
better
appreciation
various
pathways
development
neurodegenerative
disorders,
thus
focusing
on
drug
discovery
research
for
targeted
therapy
central
nervous
system
(CNS).
Although
BBB
functions
as
shield
prevent
toxins
blood
from
reaching
brain,
delivery
CNS
is
hindered
by
its
presence.
Owing
this,
formulation
approaches,
use
lipid-based
nanocarriers,
been
proposed
address
shortcomings
permeation
CNS-targeted
therapy,
showing
potential
carriers
translation
into
clinical
use.
Nevertheless,
date,
none
nanocarriers
has
granted
market
authorization
following
successful
completion
all
stages
trials.
While
aforementioned
benefits
using
underscores
need
fast-track
their
translational
practice,
technological
be
initiated
achieve
appropriate
capacity
scale-up
production
affordable
dosage
forms.
Frontiers in Cell and Developmental Biology,
Journal Year:
2022,
Volume and Issue:
10
Published: Sept. 2, 2022
In
recent
decades,
research
scientists,
molecular
biologists,
and
pharmacologists
have
placed
a
strong
emphasis
on
cutting-edge
nanostructured
materials
technologies
to
increase
medicine
delivery
the
central
nervous
system
(CNS).
The
application
of
nanoscience
for
treatment
neurodegenerative
diseases
(NDs)
such
as
Alzheimer’s
disease
(AD),
Parkinson’s
(PD),
multiple
sclerosis
(MS),
Huntington’s
(HD),
brain
cancer,
hemorrhage
has
potential
transform
care.
Multiple
studies
indicated
that
nanomaterials
can
be
used
successfully
treat
CNS
disorders
in
case
neurodegeneration.
Nanomedicine
development
cure
degenerative
inflammatory
is
critical.
Nanoparticles
may
act
drug
transporter
precisely
target
sick
sub-regions,
boosting
therapy
success.
It
important
develop
strategies
penetrate
blood–brain
barrier
(BBB)
improve
effectiveness
medications.
One
probable
tactics
use
different
nanoscale
materials.
These
nano-based
pharmaceuticals
offer
low
toxicity,
tailored
delivery,
high
stability,
loading
capacity.
They
also
therapeutic
effectiveness.
A
few
examples
many
kinds
forms
been
widely
employed
neurological
include
quantum
dots,
dendrimers,
metallic
nanoparticles,
polymeric
carbon
nanotubes,
liposomes,
micelles.
unique
qualities,
including
sensitivity,
selectivity,
ability
traverse
BBB
when
nano-sized
particles,
make
these
nanoparticles
useful
imaging
NDs.
Multifunctional
carrying
pharmacological
medications
serve
two
purposes:
they
medication
distribution
while
enabling
cell
dynamics
pharmacokinetic
study.
However,
because
wide-ranging
clinical
implications,
safety
concerns
persist,
limiting
any
translation.
evidence
using
nanotechnology
create
systems
could
pass
across
deliver
chemicals
was
examined
this
